Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1B/2A Study of CTO1681 for the Prevention and Treatment of Cytokine Release Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy

NCT05905328 is registered in ClinicalTrials.gov with CytoAgents, Inc. as lead sponsor.

NCT NCT05905328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05905328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1B/2A Study of CTO1681 for the Prevention and Treatment of Cytokine Release Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy
Lead sponsor
CytoAgents, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 28, 2023
Completion date
June 30, 2027
Enrollment
54 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cytokine release syndrome